Aravind Asokan - Publications

Affiliations: 
Biochemistry and Biophysics University of North Carolina, Chapel Hill, Chapel Hill, NC 
Area:
General Biophysics, Biochemistry, Virology Biology

68 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Nelson CE, Wu Y, Gemberling MP, Oliver ML, Waller MA, Bohning JD, Robinson-Hamm JN, Bulaklak K, Castellanos Rivera RM, Collier JH, Asokan A, Gersbach CA. Long-term evaluation of AAV-CRISPR genome editing for Duchenne muscular dystrophy. Nature Medicine. PMID 30778238 DOI: 10.1038/s41591-019-0344-3  0.56
2018 Mestre H, Hablitz LM, Xavier AL, Feng W, Zou W, Pu T, Monai H, Murlidharan G, Castellanos Rivera RM, Simon MJ, Pike MM, Plá V, Du T, Kress BT, Wang X, ... ... Asokan A, et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. Elife. 7. PMID 30561329 DOI: 10.7554/eLife.40070  0.56
2018 Meganck RM, Borchardt EK, Castellanos Rivera RM, Scalabrino ML, Wilusz JE, Marzluff WF, Asokan A. Tissue-Dependent Expression and Translation of Circular RNAs with Recombinant AAV Vectors In Vivo. Molecular Therapy. Nucleic Acids. 13: 89-98. PMID 30245471 DOI: 10.1016/j.omtn.2018.08.008  0.56
2017 Albright BH, Storey CM, Murlidharan G, Castellanos Rivera RM, Berry GE, Madigan VJ, Asokan A. Mapping the Structural Determinants Required for AAVrh.10 Transport across the Blood-Brain Barrier. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 29175157 DOI: 10.1016/j.ymthe.2017.10.017  0.56
2017 Tse LV, Klinc KA, Madigan VJ, Castellanos Rivera RM, Wells LF, Havlik LP, Smith JK, Agbandje-McKenna M, Asokan A. Structure-guided evolution of antigenically distinct adeno-associated virus variants for immune evasion. Proceedings of the National Academy of Sciences of the United States of America. PMID 28559317 DOI: 10.1073/pnas.1704766114  0.56
2016 Berry GE, Asokan A. Cellular transduction mechanisms of adeno-associated viral vectors. Current Opinion in Virology. 21: 54-60. PMID 27544821 DOI: 10.1016/j.coviro.2016.08.001  0.8
2016 Tseng YS, Vliet KV, Rao L, McKenna R, Byrne BJ, Asokan A, Agbandje-McKenna M. Generation and characterization of anti-AAV8 and anti-AAV9 monoclonal antibodies. Journal of Virological Methods. PMID 27424005 DOI: 10.1016/j.jviromet.2016.07.009  0.36
2016 Pierson EE, Keifer DZ, Asokan A, Jarrold MF. Resolving Adeno-Associated Viral Particle Diversity With Charge Detection Mass Spectrometry. Analytical Chemistry. PMID 27310298 DOI: 10.1021/acs.analchem.6b00883  0.8
2016 Madigan VJ, Asokan A. Engineering AAV receptor footprints for gene therapy. Current Opinion in Virology. 18: 89-96. PMID 27262111 DOI: 10.1016/j.coviro.2016.05.001  0.8
2016 de Leeuw CN, Korecki AJ, Berry GE, Hickmott JW, Lam SL, Lengyell TC, Bonaguro RJ, Borretta LJ, Chopra V, Chou AY, D'Souza CA, Kaspieva O, Laprise S, McInerny SC, Portales-Casamar E, ... ... Asokan A, et al. rAAV-compatible MiniPromoters for restricted expression in the brain and eye. Molecular Brain. 9: 52. PMID 27164903 DOI: 10.1186/s13041-016-0232-4  0.56
2016 Huang LY, Patel A, Ng R, Miller EB, Halder S, McKenna R, Asokan A, Agbandje-McKenna M. Characterization of the Adeno-associated virus 1 and 6 sialic acid binding site. Journal of Virology. PMID 26962225 DOI: 10.1128/JVI.00161-16  0.36
2016 Vance M, Llanga T, Bennett W, Woodard K, Murlidharan G, Chungfat N, Asokan A, Gilger B, Kurtzberg J, Samulski RJ, Hirsch ML. AAV Gene Therapy for MPS1-associated Corneal Blindness. Scientific Reports. 6: 22131. PMID 26899286 DOI: 10.1038/srep22131  0.36
2016 Murlidharan G, Samulski RJ, Asokan A. Gene therapy of CNS disorders using recombinant AAV vectors Translational Neuroscience: Fundamental Approaches For Neurological Disorders. 9-24. DOI: 10.1007/978-1-4899-7654-3_2  0.8
2015 Nelson CE, Hakim CH, Ousterout DG, Thakore PI, Moreb EA, Rivera RM, Madhavan S, Pan X, Ran FA, Yan WX, Asokan A, Zhang F, Duan D, Gersbach CA. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science (New York, N.Y.). PMID 26721684 DOI: 10.1126/science.aad5143  0.56
2015 Berry GE, Asokan A. Chemical Modulation of Endocytic Sorting Augments Adeno-Associated Viral Transduction. The Journal of Biological Chemistry. PMID 26527686 DOI: 10.1074/jbc.M115.687657  0.8
2015 Borchardt EK, Vandoros LA, Huang M, Lackey PE, Marzluff WF, Asokan A. Controlling mRNA stability and translation with the CRISPR endoribonuclease Csy4. Rna (New York, N.Y.). PMID 26354771 DOI: 10.1261/rna.051227.115  0.8
2015 Li C, Wu S, Albright B, Hirsch M, Li W, Tseng YS, Agbandje-McKenna M, McPhee S, Asokan A, Samulski RJ. Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. PMID 26220272 DOI: 10.1038/mt.2015.134  0.36
2015 Tse LV, Moller-Tank S, Asokan A. Strategies to circumvent humoral immunity to adeno-associated viral vectors. Expert Opinion On Biological Therapy. 15: 845-55. PMID 25985812 DOI: 10.1517/14712598.2015.1035645  0.8
2015 Hemphill J, Borchardt EK, Brown K, Asokan A, Deiters A. Optical Control of CRISPR/Cas9 Gene Editing. Journal of the American Chemical Society. 137: 5642-5. PMID 25905628 DOI: 10.1021/ja512664v  0.8
2015 Murlidharan G, Corriher T, Ghashghaei HT, Asokan A. Unique glycan signatures regulate adeno-associated virus tropism in the developing brain. Journal of Virology. 89: 3976-87. PMID 25631075 DOI: 10.1128/JVI.02951-14  0.8
2015 Shen S, Berry GE, Castellanos Rivera RM, Cheung RY, Troupes AN, Brown SM, Kafri T, Asokan A. Functional analysis of the putative integrin recognition motif on adeno-associated virus 9. The Journal of Biological Chemistry. 290: 1496-504. PMID 25404742 DOI: 10.1074/jbc.M114.608281  0.8
2015 Li C, Wu S, Albright B, Hirsch M, Li W, Tseng YS, Agbandje-McKenna M, McPhee S, Asokan A, Samulski RJ. Development of Patient-specific AAV Vectors After Neutralizing Antibody Selection for Enhanced Muscle Gene Transfer Molecular Therapy. DOI: 10.1038/mt.2015.134  0.8
2014 Murlidharan G, Samulski RJ, Asokan A. Biology of adeno-associated viral vectors in the central nervous system. Frontiers in Molecular Neuroscience. 7: 76. PMID 25285067 DOI: 10.3389/fnmol.2014.00076  0.8
2014 Pleticha J, Heilmann LF, Evans CH, Asokan A, Samulski RJ, Beutler AS. Preclinical toxicity evaluation of AAV for pain: evidence from human AAV studies and from the pharmacology of analgesic drugs. Molecular Pain. 10: 54. PMID 25183392 DOI: 10.1186/1744-8069-10-54  0.8
2014 Ishikawa K, Fish KM, Tilemann L, Rapti K, Aguero J, Santos-Gallego CG, Lee A, Karakikes I, Xie C, Akar FG, Shimada YJ, Gwathmey JK, Asokan A, McPhee S, Samulski J, et al. Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure. Molecular Therapy : the Journal of the American Society of Gene Therapy. 22: 2038-45. PMID 25023328 DOI: 10.1038/mt.2014.127  0.8
2014 O'Reilly M, Federoff HJ, Fong Y, Kohn DB, Patterson AP, Ahmed N, Asokan A, Boye SE, Crystal RG, De Oliveira S, Gargiulo L, Harper SQ, Ikeda Y, Jambou R, Montgomery M, et al. Gene therapy: charting a future course--summary of a National Institutes of Health Workshop, April 12, 2013. Human Gene Therapy. 25: 488-97. PMID 24773122 DOI: 10.1089/hum.2014.045  0.8
2013 Asokan A, Samulski RJ. An emerging adeno-associated viral vector pipeline for cardiac gene therapy. Human Gene Therapy. 24: 906-13. PMID 24164238 DOI: 10.1089/hum.2013.2515  0.8
2013 Shen S, Troupes AN, Pulicherla N, Asokan A. Multiple roles for sialylated glycans in determining the cardiopulmonary tropism of adeno-associated virus 4. Journal of Virology. 87: 13206-13. PMID 24067974 DOI: 10.1128/JVI.02109-13  0.8
2013 Shen S, Horowitz ED, Troupes AN, Brown SM, Pulicherla N, Samulski RJ, Agbandje-McKenna M, Asokan A. Engraftment of a galactose receptor footprint onto adeno-associated viral capsids improves transduction efficiency. The Journal of Biological Chemistry. 288: 28814-23. PMID 23940044 DOI: 10.1074/jbc.M113.482380  0.8
2013 Horowitz ED, Rahman KS, Bower BD, Dismuke DJ, Falvo MR, Griffith JD, Harvey SC, Asokan A. Biophysical and ultrastructural characterization of adeno-associated virus capsid uncoating and genome release. Journal of Virology. 87: 2994-3002. PMID 23269804 DOI: 10.1128/JVI.03017-12  0.8
2012 Shen S, Bryant KD, Sun J, Brown SM, Troupes A, Pulicherla N, Asokan A. Glycan binding avidity determines the systemic fate of adeno-associated virus type 9. Journal of Virology. 86: 10408-17. PMID 22787229 DOI: 10.1128/JVI.01155-12  0.8
2012 Li C, Diprimio N, Bowles DE, Hirsch ML, Monahan PE, Asokan A, Rabinowitz J, Agbandje-McKenna M, Samulski RJ. Single amino acid modification of adeno-associated virus capsid changes transduction and humoral immune profiles. Journal of Virology. 86: 7752-9. PMID 22593151 DOI: 10.1128/JVI.00675-12  0.8
2012 Denard J, Beley C, Kotin R, Lai-Kuen R, Blot S, Leh H, Asokan A, Samulski RJ, Moullier P, Voit T, Garcia L, Svinartchouk F. Human galectin 3 binding protein interacts with recombinant adeno-associated virus type 6. Journal of Virology. 86: 6620-31. PMID 22496229 DOI: 10.1128/JVI.00297-12  0.8
2012 Horowitz ED, Finn MG, Asokan A. Tyrosine cross-linking reveals interfacial dynamics in adeno-associated viral capsids during infection. Acs Chemical Biology. 7: 1059-66. PMID 22458529 DOI: 10.1021/cb3000265  0.8
2012 Pulicherla N, Kota P, Dokholyan NV, Asokan A. Intra- and inter-subunit disulfide bond formation is nonessential in adeno-associated viral capsids. Plos One. 7: e32163. PMID 22389684 DOI: 10.1371/journal.pone.0032163  0.8
2012 Asokan A, Schaffer DV, Samulski RJ. The AAV vector toolkit: poised at the clinical crossroads. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 699-708. PMID 22273577 DOI: 10.1038/mt.2011.287  0.8
2012 Li C, Narkbunnam N, Samulski RJ, Asokan A, Hu G, Jacobson LJ, Manco-Johnson MJ, Monahan PE. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia. Gene Therapy. 19: 288-94. PMID 21697954 DOI: 10.1038/gt.2011.90  0.8
2011 Gray SJ, Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. Production of recombinant adeno-associated viral vectors and use in in vitro and in vivo administration. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.17. PMID 21971848 DOI: 10.1002/0471142301.ns0417s57  0.8
2011 Kapoor A, Hornig M, Asokan A, Williams B, Henriquez JA, Lipkin WI. Bocavirus episome in infected human tissue contains non-identical termini. Plos One. 6: e21362. PMID 21738642 DOI: 10.1371/journal.pone.0021362  0.8
2011 Pulicherla N, Asokan A. Peptide affinity reagents for AAV capsid recognition and purification. Gene Therapy. 18: 1020-4. PMID 21490687 DOI: 10.1038/gt.2011.46  0.8
2011 Horowitz ED, Weinberg MS, Asokan A. Glycated AAV vectors: chemical redirection of viral tissue tropism. Bioconjugate Chemistry. 22: 529-32. PMID 21388193 DOI: 10.1021/bc100477g  0.8
2011 Pulicherla N, Shen S, Yadav S, Debbink K, Govindasamy L, Agbandje-McKenna M, Asokan A. Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Molecular Therapy : the Journal of the American Society of Gene Therapy. 19: 1070-8. PMID 21364538 DOI: 10.1038/mt.2011.22  0.8
2011 Shen S, Bryant KD, Brown SM, Randell SH, Asokan A. Terminal N-linked galactose is the primary receptor for adeno-associated virus 9. The Journal of Biological Chemistry. 286: 13532-40. PMID 21330365 DOI: 10.1074/jbc.M110.210922  0.8
2011 Phillips JL, Hegge J, Wolff JA, Samulski RJ, Asokan A. Systemic gene transfer to skeletal muscle using reengineered AAV vectors. Methods in Molecular Biology (Clifton, N.J.). 709: 141-51. PMID 21194026 DOI: 10.1007/978-1-61737-982-6_9  0.8
2010 Asokan A. Reengineered AAV vectors: old dog, new tricks. Discovery Medicine. 9: 399-403. PMID 20515607  0.8
2010 Asokan A, Conway JC, Phillips JL, Li C, Hegge J, Sinnott R, Yadav S, DiPrimio N, Nam HJ, Agbandje-McKenna M, McPhee S, Wolff J, Samulski RJ. Reengineering a receptor footprint of adeno-associated virus enables selective and systemic gene transfer to muscle. Nature Biotechnology. 28: 79-82. PMID 20037580 DOI: 10.1038/nbt.1599  0.8
2009 Li C, Goudy K, Hirsch M, Asokan A, Fan Y, Alexander J, Sun J, Monahan P, Seiber D, Sidney J, Sette A, Tisch R, Frelinger J, Samulski RJ. Cellular immune response to cryptic epitopes during therapeutic gene transfer. Proceedings of the National Academy of Sciences of the United States of America. 106: 10770-4. PMID 19541644 DOI: 10.1073/pnas.0902269106  0.8
2009 Li C, Hirsch M, DiPrimio N, Asokan A, Goudy K, Tisch R, Samulski RJ. Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. Journal of Virology. 83: 6817-24. PMID 19369348 DOI: 10.1128/JVI.00278-09  0.8
2009 Li C, Hirsch M, Carter P, Asokan A, Zhou X, Wu Z, Samulski RJ. A small regulatory element from chromosome 19 enhances liver-specific gene expression. Gene Therapy. 16: 43-51. PMID 18701910 DOI: 10.1038/gt.2008.134  0.8
2008 Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Eugene Redmond D, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-1260. PMID 28178482 DOI: 10.1038/mt.2008.100  0.36
2008 Asokan A, Johnson JS, Li C, Samulski RJ. Bioluminescent virion shells: new tools for quantitation of AAV vector dynamics in cells and live animals. Gene Therapy. 15: 1618-22. PMID 18668144 DOI: 10.1038/gt.2008.127  0.8
2008 Li W, Asokan A, Wu Z, Van Dyke T, DiPrimio N, Johnson JS, Govindaswamy L, Agbandje-McKenna M, Leichtle S, Redmond DE, McCown TJ, Petermann KB, Sharpless NE, Samulski RJ. Engineering and selection of shuffled AAV genomes: a new strategy for producing targeted biological nanoparticles. Molecular Therapy : the Journal of the American Society of Gene Therapy. 16: 1252-60. PMID 18500254 DOI: 10.1038/mt.2008.100  0.8
2008 DiPrimio N, Asokan A, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Surface loop dynamics in adeno-associated virus capsid assembly. Journal of Virology. 82: 5178-89. PMID 18367523 DOI: 10.1128/JVI.02721-07  0.8
2007 Choi VW, Asokan A, Haberman RA, Samulski RJ. Production of recombinant adeno-associated viral vectors. Current Protocols in Human Genetics / Editorial Board, Jonathan L. Haines ... [Et Al.]. Unit 12.9. PMID 18428408 DOI: 10.1002/0471142905.hg1209s53  0.8
2007 Choi VW, Asokan A, Haberman RA, Samulski RJ. Production of recombinant adeno-associated viral vectors for in vitro and in vivo use. Current Protocols in Molecular Biology / Edited by Frederick M. Ausubel ... [Et Al.]. Unit 16.25. PMID 18265393 DOI: 10.1002/0471142727.mb1625s78  0.8
2007 Li C, Hirsch M, Asokan A, Zeithaml B, Ma H, Kafri T, Samulski RJ. Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. Journal of Virology. 81: 7540-7. PMID 17475652 DOI: 10.1128/JVI.00529-07  0.8
2006 Choi VW, Asokan A, Haberman RA, McCown TJ, Samulski RJ. Production of recombinant adeno-associated viral vectors and use for in vitro and in vivo administration. Current Protocols in Neuroscience / Editorial Board, Jacqueline N. Crawley ... [Et Al.]. Unit 4.17. PMID 18428636 DOI: 10.1002/0471142301.ns0417s35  0.8
2006 Wu Z, Asokan A, Grieger JC, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Single amino acid changes can influence titer, heparin binding, and tissue tropism in different adeno-associated virus serotypes. Journal of Virology. 80: 11393-7. PMID 16943302 DOI: 10.1128/JVI.01288-06  0.8
2006 Asokan A, Hamra JB, Govindasamy L, Agbandje-McKenna M, Samulski RJ. Adeno-associated virus type 2 contains an integrin alpha5beta1 binding domain essential for viral cell entry. Journal of Virology. 80: 8961-9. PMID 16940508 DOI: 10.1128/JVI.00843-06  0.8
2006 Wu Z, Asokan A, Samulski RJ. Adeno-associated virus serotypes: vector toolkit for human gene therapy. Molecular Therapy : the Journal of the American Society of Gene Therapy. 14: 316-27. PMID 16824801 DOI: 10.1016/j.ymthe.2006.05.009  0.8
2006 Asokan A, Samulski RJ. AAV does the shuffle. Nature Biotechnology. 24: 158-60. PMID 16465157 DOI: 10.1038/nbt0206-158  0.8
2006 Asokan A, Cheung R, Cho MJ. Strategies for the Cytosolic Delivery of Macromolecules: An Overview Handbook of Pharmaceutical Biotechnology. 279-296. DOI: 10.1002/9780470117118.ch3c  0.8
2005 Asokan A, Cho MJ. Cytosolic delivery of macromolecules 4. Head group-dependent membrane permeabilization by pH-sensitive detergents. Journal of Controlled Release : Official Journal of the Controlled Release Society. 106: 146-53. PMID 15979190 DOI: 10.1016/j.jconrel.2005.04.010  0.8
2005 Asokan A, Samulski RJ. From crystal structure to clinic: highlights of the Tenth International Parvovirus Workshop. Molecular Therapy : the Journal of the American Society of Gene Therapy. 11: 656-60. PMID 15892211 DOI: 10.1016/j.ymthe.2005.03.014  0.8
2004 Asokan A, Cho MJ. Cytosolic delivery of macromolecules. 3. Synthesis and characterization of acid-sensitive bis-detergents. Bioconjugate Chemistry. 15: 1166-73. PMID 15546181 DOI: 10.1021/bc049880n  0.8
2003 Asokan A, Cho MJ. Cytosolic delivery of macromolecules. II. Mechanistic studies with pH-sensitive morpholine lipids. Biochimica Et Biophysica Acta. 1611: 151-60. PMID 12659956 DOI: 10.1016/S0005-2736(03)00050-6  0.8
2003 Chen FJ, Asokan A, Cho MJ. Cytosolic delivery of macromolecules: I. Synthesis and characterization of pH-sensitive acyloxyalkylimidazoles. Biochimica Et Biophysica Acta. 1611: 140-50. PMID 12659955 DOI: 10.1016/S0005-2736(03)00049-X  0.8
2002 Asokan A, Cho MJ. Exploitation of intracellular pH gradients in the cellular delivery of macromolecules. Journal of Pharmaceutical Sciences. 91: 903-13. PMID 11948528 DOI: 10.1002/jps.10095  0.8
Show low-probability matches.